All In Biotech

Drug Trial Radar · NCT04914117

A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours

Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Nov 29, 2021

Primary completion

Nov 15, 2022

Study completion Mar 11, 2023

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered dose (MAD), and to define the recommended Phase II dose (RP2D).

Conditions

  • Unresectable Solid Tumor
  • Metastatic Solid Tumor
  • Locally Advanced Solid Tumor

Interventions

  • RC118 for injectionDrug

    RC118 will be administered intravenously (IV) on Day 1 of every 14-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD/MAD based on number of dose-limiting toxicities (DLTs)Time frame: Up to 18 months
  2. Determine Recommended Phase 2 Dose (RP2D)Time frame: Up to 18 months
  3. Adverse EventsTime frame: Up to 18 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Remegen Site #12

    Macquarie Park, New South Wales, Australia

  • Remegen Site #14

    Bedford Park, South Australia, Australia

  • Remegen Site #13

    Frankston, Victoria, Australia

  • Remegen Site #11

    Malvern, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.